What is the effect of adjusting epirubicin doses for body surface area?

British Journal of Cancer

Volumn 78, Issue 5, 1998, Pages 662-666

  Dobbs, N A ^a,c   Twelves, C J ^a,b  

^a GUY S HOSPITAL   (United Kingdom)

^b CRC Department of Medical Oncology   (United Kingdom)

^c CHURCHILL HOSPITAL   (United Kingdom)

Author keywords

Epirubicin; Pharmacodynamics; Pharmacokinetics; Surface area

Indexed keywords

EPIRUBICIN;

ADULT; AGED; AREA UNDER THE CURVE; ARTICLE; BODY SURFACE; BONE MARROW SUPPRESSION; BREAST CANCER; CANCER CHEMOTHERAPY; CLINICAL TRIAL; DOSE CALCULATION; DRUG CLEARANCE; DRUG DETERMINATION; FEMALE; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; INTRAVENOUS DRUG ADMINISTRATION; MAJOR CLINICAL STUDY; NEUTROPENIA; PHARMACODYNAMICS; PRIORITY JOURNAL;

EID: 0031926978     PISSN: 00070920     EISSN: None     Source Type: Journal    
DOI: 10.1038/bjc.1998.556     Document Type: Article

References (17)

1. Ackland SP, Ratain MJ and Vozelgang NJ (1989) Pharmacokinetics and pharmacodynamics of long-term continuous infusion doxorubicin. Clin Pharmacol and Ther 45: 340-347
2. Allerheiligen S, Johnson R, Hatcher B, Freeman P, Tarassof MV and Dorr A (1994) Gemcitabine pharmacokinetics are influenced by gender, body surface area (BSA), and duration of infusion. Proc Am Soc Clin Oncol 13: 339
3. Bruno R, Hille D, Thomas L et al (1995) Population pharmacokinetics/pharmacodynamics (PK/PD) of docetaxel (Taxotere) in phase II studies. Proc Am Soc Clin Oncol 14: 457
4. Cosolo W, Morgan DJ, Seeman E, Zimet AS, Mckendrick JJ and Zalcberg JR (1994) Lean body mass, body surface area and epirubicin kinetics. Anti-Cancer Drugs 5: 293-297
5. Dobbs NA and Twelves CJ (1991) Measurement of epirubicin and its metabolites by high-performance liquid chromatography using an advanced sample processor. J Chrom Biomed Appl 572: 37-42
6. Dobbs NA, Twelves CJ, Gillies H, James CA, Harper PG and Rubens RD (1995a). Gender affects doxorubicin pharmacokinetics in patients with normal liver biochemistry. Cancer Chemother Pharmacol 36: 473-476
7. Dobbs NA, Twelves CJ, Cruikshank C, Curnow A, Gregory W, Richards MA and Rubens RD (1995b). Adaptive dosing for epirubicin (Epi): prospective pharmacokinetic evaluation of nomogram based on serum aspartate aminotransferase (AST). Proc Am Soc Clin Oncol 14: 366
8. Grochow LB, Baraldi C and Noe D (1990) Is dose normalization to weight or body surface area useful in adults? J Natl Cancer Inst 82: 323-325
9. Johnson A and Woollard RC (1983) Stripe: an interactive computer programme for the analysis of drug pharmacokinetics. J Pharmacol Methods 9: 193-200
10. Lotts RS and Hayton WL (1980) Estimation of creatinine clearance from serum creatinine concentration. Drug Intel Clin Pharm 12: 195-201
11. Reilly J and Workman P (1994) Is body composition an important variable in the pharmacokinetics of anticancer drugs? Cancer Chemother Pharmacol 34: 3-13
12. Robert J and Hoerni B (1983) Age dependence of the early-phase pharmacokinetics of doxorubicin. Cancer Res 43: 4467-4469
13. Robert J, Armand JP, Huet S, Kilink-Alaki M, Recondo G and Hurteloup P (1992). Pharmacokinetics and metabolism of 4′-iodo-4′-deoxydoxorubicin. Br J Cancer 10: 1183-1190
14. Twelves CJ, Dobbs NA, Michael Y, Summers LA, Gregory W, Harper PG, Rubens RD and Richards MA (1992) Clinical pharmacokinetics of epirubicin: the importance of abnormal liver biochemistry tests. Br J Cancer 66: 765-769
15. Twelves CJ, Dobbs NA, Lawrence MA, Ramirez AJ, Summerhayes M, Richards MA, Towlson KE, Rubens RD (1994) Iododoxorubicin in advanced breast cancer: a phase II evaluation of clinical activity, pharmacology and quality of life. Br J Cancer 69: 726-731
16. Wade JR, Kelman AW, Kerr DJ, Robert J and Whiting B (1992) Variability in the pharmacokinetics of epirubicin: a population analysis. Cancer Chemother Pharmacol 29: 391
17. WHO (1979) Handbook for Reporting Results of Cancer Treatment. World Health Organization: Geneva